An open multicenter, phase III study of photodynamic therapy with Metvix cream [Methyl aminolevulinate] 160 mg/g in patients with `high risk' basal cell carcinoma.

Trial Profile

An open multicenter, phase III study of photodynamic therapy with Metvix cream [Methyl aminolevulinate] 160 mg/g in patients with `high risk' basal cell carcinoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2010

At a glance

  • Drugs Methyl aminolevulinate (Primary)
  • Indications Basal cell cancer
  • Focus Therapeutic Use
  • Sponsors PhotoCure
  • Most Recent Events

    • 13 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top